Entrada Therapeutics (TRDA) Projected to Release Quarterly Earnings on Thursday

Entrada Therapeutics (NASDAQ:TRDA) is anticipated to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.98) per share and revenue of $2.30 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. On average, analysts expect Entrada Therapeutics to post ($4.03) EPS for the current fiscal year and ($3.52) EPS for the next fiscal year.

Entrada Therapeutics Price Performance

Shares of NASDAQ:TRDA opened at $4.93 on Tuesday. The business’s 50 day moving average price is $6.00 and its 200-day moving average price is $8.70. The firm has a market capitalization of $191.96 million, a PE ratio of -1.23 and a beta of -0.24. Entrada Therapeutics has a 1 year low of $4.11 and a 1 year high of $16.45.

Insider Transactions at Entrada Therapeutics

In other news, major shareholder Ventures V. L.P. 5Am sold 52,317 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $6.85, for a total value of $358,371.45. Following the completion of the sale, the insider directly owned 2,783,781 shares in the company, valued at $19,068,899.85. This represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 192,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $7.41, for a total value of $1,426,425.00. Following the completion of the sale, the insider owned 3,913,952 shares of the company’s stock, valued at $29,002,384.32. This trade represents a 4.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 714,013 shares of company stock worth $5,111,237 in the last ninety days. Insiders own 9.49% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on TRDA shares. Roth Capital restated a “buy” rating and issued a $11.00 price objective on shares of Entrada Therapeutics in a report on Wednesday, August 12th. Wall Street Zen cut shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Weiss Ratings lowered shares of Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 16th. HC Wainwright reiterated a “neutral” rating on shares of Entrada Therapeutics in a research report on Monday, October 19th. Finally, UBS Group reiterated a “neutral” rating on shares of Entrada Therapeutics in a research report on Monday, October 19th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $17.75.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc (NASDAQ:TRDA) is a biotechnology company focused on developing therapeutics designed to enter cells and address diseases caused by abnormal or missing intracellular proteins. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic payloads into target cells while helping them escape the endosome, a cellular compartment that can limit the effectiveness of some treatments.

Entrada is developing EEV-based medicines for serious diseases, particularly genetic and neuromuscular conditions.